SciELO - Scientific Electronic Library Online

 
vol.43 issue2Analysis of acenocoumarol and levofloxacin interaction in elderly institutionalized patientsOptic neuropathy associated with linezolid: systematic review of cases author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Farmacia Hospitalaria

On-line version ISSN 2171-8695Print version ISSN 1130-6343

Abstract

SANCHEZ-GUNDIN, Julia; FERNANDEZ-CARBALLIDO, Ana María; TORRES-SUAREZ, Ana Isabel  and  BARREDA-HERNANDEZ, Dolores. Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy. Farm Hosp. [online]. 2019, vol.43, n.2, pp.56-60. ISSN 2171-8695.  https://dx.doi.org/10.7399/fh.11156.

Objective:

To evaluate and to compare quality of life of patients with non-metastasic colorectal cancer treated either with FOLFOX or with XELOX scheme.

Method:

Descriptive prospective study during 24 months (October 2015-October 2017) for patients with non-metastasic colorectal cancer in chemotherapy adyuvant treatment. EORTC QLQ-C30 questionnaire was filled by patients at the beginning and at week 12 of adjuvant treatment. Variables collected: exposure (chemotherapeutic scheme administered), control (demographic data, disease data, treatment data) and response (scores obtained from the questionnaire). The data statistical analysis was carried out with the SPSS® 15.0 programme.

Results:

30 patients were included. Statistically significant differences were found in emotional role item at the middle of the treatment (FOLFOX 92 points vs. XELOX 82 points; p = 0,036). Patients with FOLFOX presented a clinically relevant worsening in terms of daily activities, constipation and insomnia. Patients treated with XELOX a clinically relevant worsening in daily activities, constipation, fatigue, nausea, vomiting, anorexia and diarrhoea were observed.

Conclusions:

Patients with XELOX scheme referred to have worse emotionally status in the middle of the adjuvant treatment than patients treated with FOLFOX scheme and presented a worsening in items fatigue, nausea, vomiting, anorexia and diarrhoea.

Keywords : Adyuvant treatment; Colorectal cancer; FOLFOX; Quality of life; Safety; XELOX.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf )